β‐Galactosidase deficiency: An approach to chaperone therapy
- 1 April 2006
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 29 (2-3) , 471-476
Abstract
Summary: We propose a new molecular therapeutic approach to lysosomal diseases with severe neurological manifestations. Some low‐molecular‐weight compounds, acting as competitive inhibitors of a lysosomal enzyme in vitro, were found to stabilize and restore catalytic activities of the enzyme molecule as a molecular chaperone. We started this trial first in Fabry disease (generalized vasculopathy) using galactose and 1‐deoxygalactonojirimycin, and then in β‐galactosidase deficiency disorders (β‐galactosidosis) with generalized neurosomatic and/or systemic skeletal manifestations (GM1‐gangliosidosis and Morquio B disease), using a newly developed chemical compound N‐octyl‐4‐epi‐β‐valienamine (NOEV). Administration of this chaperone compound resulted in elevation of intracellular enzyme activity in cultured fibroblasts from patients and genetically engineered model mice. In addition, substrate storage was improved after NOEV had been transported into the brain tissue via the blood–brain barrier. We hope this new approach (chemical chaperone therapy) will be useful for certain patients with β‐galactosidosis and potentially other lysosomal storage diseases with central nervous system involvement.Keywords
This publication has 25 references indexed in Scilit:
- Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis miceJournal of Lipid Research, 2005
- N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- Development of lysosomal storage in mice with targeted disruption of the β-galactosidase gene: a model of human GM1-gangliosidosisBrain and Development, 2001
- Galactonojirimycin derivatives restore mutant human β-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouseBrain and Development, 2001
- Chemical modification of β-glucocerebrosidase inhibitor N-octyl-β-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivativesBioorganic & Medicinal Chemistry, 1998
- Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic ReticulumBiochemical and Biophysical Research Communications, 1996
- Galactose Stabilizes Various Missense Mutants of α-Galactosidase in Fabry DiseaseBiochemical and Biophysical Research Communications, 1995
- Synthesis of glucosylceramide analogues: imino-linked 5a-carbaglycosylceramides, potent and specific glucocerebrosidase inhibitorsJournal of the Chemical Society, Chemical Communications, 1994
- Bone marrow transplantation in canine GM1 gangliosidosisClinical Genetics, 1990
- Amniotic tissue transplantation as a trial of treatment in some lysosomal storage diseasesJournal of Inherited Metabolic Disease, 1984